Evidence-Based Treatment of Cerebrovascular Disease

Introduction to Evidence-Based Medicine

William J. Powers, M.D.-- Departments of Neurology, Neurosurgery and Radiology
Washington University School of Medicine -- Presented July 11, 2006

Failure of a Biomarker as Surrogate Endpoint

The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial
(ALLHAT-LLT)

Treatment Group

	Pravastatin 40 mg/day	Usual Care	p value
Cholesterol	177.6 ± 33.8	195.5 ± 37.3	< .0005
All Deaths	631	641	.88

Back

Table of Contents

All References

References

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
JAMA 2002 Dec 18;288(23):2998-3007.